The Department is already referring cases to the Competition and Market Authority (CMA) and to strengthen our work in this area. We are considering putting measures in place to routinely and systematically monitor significant price increases of generic medicines and take action where appropriate, including the possible referral of suspected excessive pricing to the CMA, while taking into account the potential impact of any such action on the availability of medicines.
I wonder how long this takes to filter thru to the US regulators.
---looks like CXR will get to zero before VRX does. I didn't think that would happen.
carlos